Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics
ARDS Price/Volume Stats
| Current price | $0.07 | 52-week high | $0.54 |
| Prev. close | $0.06 | 52-week low | $0.05 |
| Day low | $0.06 | Volume | 7,700 |
| Day high | $0.07 | Avg. volume | 101,071 |
| 50-day MA | $0.07 | Dividend yield | N/A |
| 200-day MA | $0.10 | Market Cap | 3.12M |
ARDS Stock Price Chart Interactive Chart >
Aridis Pharmaceuticals Inc. (ARDS) Company Bio
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.
Latest ARDS News From Around the Web
Below are the latest news stories about ARIDIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARDS as an investment opportunity.
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). |
Aridis (ARDS) Up on Regulatory Update for Pneumonia DrugAridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population. |
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacteri |
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateLOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023. First Quarter & Subsequent Highlights Met primary safety and secondary pharmacokinetics endpoints in AR-501 Phase 2a study in cystic fibrosis (CF). CF patients achiev |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning! |
ARDS Price Returns
| 1-mo | -6.42% |
| 3-mo | -7.28% |
| 6-mo | -19.08% |
| 1-year | -62.98% |
| 3-year | -98.87% |
| 5-year | -99.30% |
| YTD | -0.14% |
| 2023 | -94.06% |
| 2022 | -49.36% |
| 2021 | -61.61% |
| 2020 | 36.40% |
| 2019 | -59.87% |
Continue Researching ARDS
Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...